The clinical benefits of DNMT inhibitors include the reactivation of silenced tumor suppressor genes, induction of cellular differentiation, and promotion of cancer cell death. Patients with MDS and AML have shown improved survival rates and better overall responses to treatment. Additionally, DNMT inhibitors can sensitize tumor cells to other forms of chemotherapy and immunotherapy.
